Cambridge Life Sciences (CLS) launches ELISA tests for ACL:
This article was originally published in Clinica
Cambridge Life Sciences (UK) has launched Autozyme ACL, a new range of three ELISA tests for the measurement of IgA, IgG and IgM anti-cardiolipin antibodies (ACL). Research indicates that raised levels of ACL IgA, IgG and IgM are associated with venous and arterial thrombosis, thrombocytopaeni, recurrent foetal loss and myocardial infarction, as well as neurological conditions. The Autozyme assays are compatible, and can be run simultaneously.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.